Introduction
Cytomegalovirus (CMV) is a ubiquitous herpesvirus that generally causes asymptomatic or mildly symptomatic infection in immunocompetent hosts. In contrast, CMV infection in immunocompromised patients carries high morbidity and mortality. Before the introduction of highly active antiretroviral therapy (HAART), acquired immunodeficiency syndrome (AIDS) patients constituted the largest group severely affected by CMV, with a 10% annual incidence of sight-or life-threatening disease. 1, 2 The introduction of HAART in 1995 -1996 caused a significant reduction in the incidence of AIDS-associated opportunistic infections including CMV. 3 At the same time, new manifestations of opportunistic infections were identified and classified as immune recovery syndromes. We compare the clinical spectrum of CMV before and after HAART, while focusing on immune reconstitution.
CMV infection in patients with HIV before the introduction of HAART
Overview of clinical and epidemiological characteristics CMV disease typically occurs when latent virus reactivates in AIDS patients with <100 CD4+ T cells/mm 3 . CMV infection in patients with <100 CD4+ cells/mm 3 can be asymptomatic, or can cause non-specific symptoms such as fever and malaise or localized end-organ disease. 4 The most common manifestation of CMV in HIV-infected individuals was retinitis, which occurred in 40% of AIDS patients and represented 85% of all CMV end-organ diseases. 1 Gastrointestinal tract manifestations accounted for 10% of CMV disease in AIDS patients and the remainder consisted of neurological disorders, pneumonitis, hepatitis and adrenalitis.
Antiviral therapy against CMV relies on several effective drugs, such as ganciclovir, foscarnet and cidofovir. Due to intense immunosuppression and frequent viral reactivations, CMV disease tended to have a relentlessly progressive course 5 and, therefore, patients with sight-or life-threatening manifestations were typically maintained on low-dose antiviral therapy indefinitely. 6 However, the virus frequently developed resistance to the antivirals, causing relapse of clinical symptoms. 7, 8 Both symptomatic and asymptomatic CMV infections were associated with increased risk of death in AIDS patients. 9 This might be due to organ failure related to CMV end-organ disease; because CMV active infection might be a marker of extremely severe immunosuppression, which ultimately leads to the fatal outcome of the patient; or because CMV infection might have down-regulatory effects on the immune system and thus predispose to death.
Viral reactivations
The factors that trigger CMV reactivation in AIDS patients are incompletely understood. At least one mechanism is tumour necrosis factor (TNF)-a-mediated stimulation of the host cell, leading to nuclear factor kB (NF-kB) intranuclear accumulation and activation of CMV DNA replication. 10 This might explain the high prevalence of CMV reactivation in conditions associated with increased synthesis of TNF-a, such as HIV infection.
CMV reactivations were most frequent in HIV-infected individuals with <100 CD4+ cells/mm 3 . When monitored systematically, 45-60% of these patients developed one or more episodes of circulating CMV DNA over a period of 6-12 months. 11, 12 Although CMV reactivations played a crucial role in the development of end-organ disease 13, 14 of AIDS patients, CMV replication was sometimes asymptomatic and self-limited. The positive predictive value of finding CMV DNA in plasma and white blood cells by PCR was 60% and 40%, respectively. High titres of circulating CMV DNA increased the risk of end-organ disease. 15 Measures that prevented viraemia also decreased the incidence of the disease. Both oral and parenteral ganciclovir were successfully used for this purpose. 15 However, the cost of prophylactic therapy for HIV-infected patients at risk of CMV disease before HAART was prohibitive. 16 
Immune responses
The integrity of the immune system is a decisive factor in the development of CMV end-organ disease. In CMV viraemic AIDS patients stratified by CD4+ counts of <50, 50 -100 and >100 cells/mm 3 , the incidence of CMV end-organ disease over a period of 6 months was 25%, 5.5% and 1.3%, respectively. 4, 11 Not all individuals with AIDS and CMV reactivation progressed to end-organ disease and the factors that ultimately determined the development of symptoms are incompletely understood. CMV-seropositive AIDS patients who lacked lymphocyte proliferative responses to CMV had a higher risk of developing CMV end-organ disease, 17 suggesting a protective role for cellmediated immunity. In contrast, anti-CMV neutralizing and total antibody titres were comparable in AIDS patients to levels in healthy controls and in patients with less advanced HIV infection. 18, 19 Furthermore, administration of neutralizing anti-CMV monoclonal antibodies did not prevent or modify the course of the disease. 20 These data argue against a protective role for CMV-specific humoral immunity. Many other immune parameters are altered in HIV-infected patients, but their contributions to the increased susceptibility of AIDS patients to CMV disease has not been adequately studied.
CMV infection in the era of HAART

Clinical and epidemiological features
HAART decreases HIV replication and increases CD4+ cell count. This is associated with a marked reduction in the incidence of opportunistic infections 3 and increased survival. 21 The incidence of new CMV retinitis has declined by 80%, and survival in patients with CMV retinitis has increased by 93%. 22 Risk factors for CMV end-organ disease in the HAART era continue to be CD4+ counts of <50-100 cells/mm 3 , 23 -25 and CMV reactivation 23, 26 (Table 1 ). In addition, an HIV viral load (VL) of >10 000 RNA copies/mL is associated with new CMV disease in HAART recipients. 23 Current guidelines recommend discontinuation of secondary prophylaxis in HAART recipients with a sustained (> _ 6 months) increase in CD4+ T cells to levels of >100 -150 cells/mm 3 . 27 However, there are several reports of CMV retinitis occurring or progressing in patients taking HAART in the presence of CD4+ T cell counts of >100 cells/mm 3 . A new clinical entity, CMV immune recovery vitritis, has been described in HAART recipients. 24, 28, 29 This disease is characterized by posterior chamber inflammation, macular and disc oedema, neovascularization, cataracts and epiretinal membrane formation. Loss of visual acuity is common. It occurs in 15-90% of patients with previous CMV retinitis who experience increases in the number of CD4+ cells on HAART.
24,30 The immunopathogenesis of this new disease is discussed below. There are conflicting data on the response to CMV antiviral treatment, 31,32 but topical corticosteroids seem to improve symptoms. 31 
Viral reactivations
HAART decreases the incidence of viraemia. 33 -35 In one study of 16 patients, HAART resulted in the disappearance of CMV DNA from circulation as detected by PCR without specific anti-CMV therapy. 36 One potential mechanism is that control of HIV replication and opportunistic infections eliminates factors that would otherwise increase CMV reactivation, 37 such as transactivation in cells co-infected with CMV and other pathogens or increased circulating TNF-a. In addition, we showed that CMVspecific interferon-g production by in vitro-stimulated peripheral blood mononuclear cells was associated with a decreased risk of CMV reactivation in HAART recipients, arguing in favour of immunological control of CMV replication. The two mechanisms are not mutually exclusive and might jointly contribute to the decrease in CMV reactivation.
Immune responses
During the first 3 months of HAART both memory and naive circulating CD4+ cells increase. 38 There is an initial increase, followed by a decrease in circulating CD8+ cells. Activation markers on circulating T cells and TNF-a serum levels decrease. 39 Three to 6 months after HAART, patients reacquire delayed type hypersensitivity responses and in vitro lymphocyte proliferation assay (LPA) to microbial antigens. 40 Both cellular and humoral CMV-specific immune reconstitution has been demonstrated in HAART recipients. 41 -43 CMV LPA responses increase with higher CD4+ cell counts and there is no significant HIV load < 10 000 RNA copies/mL CMV-specific qualitative interferon-g production in bulk mononuclear cell culture circulating CD4+ interferon-g-producing cells circulating CD8+ interferon-g-producing cells absence of CMV DNA in blood association between nadir CD4+ cells and CMV-specific immune reconstitution (A. Weinberg, unpublished results). However, immune restoration is incomplete, as illustrated by the inconsistency of CMV-specific CD4+-mediated proliferative responses, 44, 45 the dissociation between in vitro mononuclear cell proliferation and cytokine production 44 and the persistence of high levels of circulating CMV-specific CD8+ T lymphocytes. 46 The mechanisms that account for incomplete immune reconstitution in HIV-infected patients are under investigation. There is evidence for both pathogen-specific and generalized immune defects. We described a HAART recipient with recurrent CMV retinitis despite an increase in circulating CD4+ T lymphocytes to >200 cells/mm 3 . This patient was unable to mount in vitro CMV-specific immune responses but had adequate Candidaspecific in vitro responses, 47 suggesting that CMV-specific clonal deletion or toleration might have occurred. However, there is also evidence that HAART recipients who reconstitute immunity against a ubiquitous agent such as Candida or CMV are more likely to reconstitute responses against other pathogens.
48,49
At the cellular level, several mechanisms have been implicated in the immune defect observed in HAART recipients. These patients have persistently high proportions of apoptotic circulating mononuclear cells despite control of HIV replication. 50 There is a marked deficit of CMV-specific CD4+ T cell production of interleukin-2 33,44,51,52 with downstream consequences on cell cycle progression 53 and proliferation. 52, 54 Furthermore, there is evidence of down-regulatory activity mediated by CD4+ 55 and CD8+ 44 T cells. The immune recovery vitritis or uveitis constitutes another example of altered immune responses in HIV-infected patients on HAART. This syndrome is characterized by exuberant retinal inflammatory infiltrates, which include CMV-specific cytotoxic T cells but also CD8+ T cells of broader specificity 56 and seems to occur in the context of increased CMV-specific Th2 responses. 57 In contrast, protection against CMV disease is conferred by Th1-specific cells. It is interesting to note that the eye, a segregated body compartment, but not the gastrointestinal or respiratory tract, is the main target of CMV-associated immune recovery syndrome. It is tempting to speculate that the barrier between the eye chambers and circulation might impair the ability to establish normal immune regulatory processes in patients undergoing immune reconstitution.
Although it is well accepted that competent CMV-specific responses are critical determinants of CMV infection outcome, a user-friendly immunological test that can predict protection against CMV disease is not yet available. Immune reconstitution of HIV-infected patients on HAART has offered ample opportunity to examine immune correlates of protection against CMV disease. CMV-stimulated interferon-g production measured in bulk cell culture supernatants 33 or by flow cytometry in CD4+ 58 or CD8+ 59 cells has shown the best correlation with protection against CMV reactivation and disease (Table 1) . Further work is needed, however, to establish the predictive value of CMVspecific interferon-g assays in clinical practice. 
